Eli Lilly Bets €2.4B on AI-Designed Drugs in New Insilico Medicine Deal

oncodaily - In a sweeping push to expand its pipeline and embrace artificial intelligence in drug discovery, Eli Lilly and Company has announced two major strategic moves: a multi-billion-dollar collaboration with Insilico […]

AI Summary: Eli Lilly struck a major partnership with Insilico Medicine to accelerate AI‑designed drug programs, providing a substantial upfront payment and committing to multiyear development milestones and potential payouts worth roughly in the billions. The deal expands Lilly’s AI drug discovery footprint and signals big pharma’s growing bet on algorithmic chemistry.